Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XePOHCAS: Prospective, randomized, multicenter, interventional trial in adult subjects with out-of-hospital cardiac arrest comparing treatment with standard-of-care post-cardiac arrest intensive care (which is targeted temperature management [TTM]) to standard-of-care post-cardiac arrest intensive care (including TTM) plus xenon by inhalation

Trial Profile

XePOHCAS: Prospective, randomized, multicenter, interventional trial in adult subjects with out-of-hospital cardiac arrest comparing treatment with standard-of-care post-cardiac arrest intensive care (which is targeted temperature management [TTM]) to standard-of-care post-cardiac arrest intensive care (including TTM) plus xenon by inhalation

Status: Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Xenon (Primary)
  • Indications Chronic brain damage
  • Focus Registrational; Therapeutic Use
  • Acronyms XePOHCAS
  • Sponsors Invero Pharma

Most Recent Events

  • 26 Mar 2025 Planned End Date changed from 15 Dec 2020 to 1 May 2030.
  • 26 Mar 2025 Planned primary completion date changed from 15 Jul 2020 to 1 Apr 2029.
  • 26 Mar 2025 Planned initiation date changed from 25 May 2018 to 1 Mar 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top